Medical Oncology Clinical Trial
Official title:
An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Verified date | April 2020 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.
Status | Completed |
Enrollment | 75 |
Est. completion date | April 18, 2019 |
Est. primary completion date | March 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects aged >/= 18 years. - Study population: - For the dose-escalation cohorts: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, have no standard therapy available - For the expansion cohort: Subjects with advanced, histologically or cytologically confirmed triple-negative breast cancer (TNBC), refractory to any standard therapy, have no standard therapy available, or subjects actively refused any standard treatment and / or if, in the judgment of the investigator, experimental treatment is clinically acceptable. - Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Life expectancy of at least 12 weeks. - Adequate bone marrow, liver, and renal functions. Exclusion Criteria: - Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study. - Evidence of peripheral neuropathy of Grade >2. - History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted). - Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management. - Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C. - History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bayer |
United States, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose (MTD) | The MTD is defined as the highest dose that can be given such that the dose-limiting toxicity (DLT) rate of the combination treatment is not more than 10% higher than the cumulative DLT rate of the standard single-agent treatment across all previous and the current cohort. | Up to 28 days (Cycle 1) | |
Primary | Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability. | After the first study drug administration and up to 30 days after the end of treatment with study drug before primary completion analysis of the study, up to 3 years | ||
Primary | Maximum observed drug concentration (Cmax) of BAY1217389 in plasma | From pre-dose up to 96 hours post-dose on C1D-8 and C1D-4; from pre-dose up to 12 hours post-dose on C1D8 and C1D9 | ||
Primary | Area under the concentration versus time curve from zero to 12 hours (AUC [0-12]) of BAY1217389 in plasma | From pre-dose up to 12 hours post-dose on C1D-4, C1D8 and C1D9 | ||
Primary | Area under the concentration versus time curve from zero to 96 hours (AUC [0-96]) of BAY1217389 in plasma | From pre-dose up to 96 hours post-dose on C1D-4 | ||
Primary | Maximum observed drug concentration (Cmax) of paclitaxel in plasma | From pre-dose up to 24 hours post-dose on C1D1 and C1D8 | ||
Primary | Area under the concentration versus time curve from zero to infinity (AUC) of paclitaxel in plasma | From pre-dose up to 24 hours post-dose on C1D1 and C1D8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02824042 -
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
|
Phase 1 | |
Completed |
NCT02253420 -
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
|
Phase 1 | |
Completed |
NCT02357953 -
Transpulmonary Thermodilution Using an Implented Central Venous Access Port
|
N/A | |
Completed |
NCT02645357 -
Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients
|
N/A | |
Recruiting |
NCT04931329 -
Onco-haematology Vigilance Card
|
||
Terminated |
NCT02138812 -
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Recruiting |
NCT05356182 -
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
|
N/A | |
Terminated |
NCT02368951 -
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
|
Phase 1 | |
Not yet recruiting |
NCT05423808 -
Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.
|
N/A | |
Terminated |
NCT02439346 -
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
|
Phase 1 | |
Recruiting |
NCT05385718 -
Ezra Faster Scan Study
|
||
Completed |
NCT02457351 -
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
|
Phase 1 | |
Completed |
NCT02906423 -
Results From a Health System-wide Implementation of a Quality of Life Questionnaire
|
N/A | |
Completed |
NCT01409135 -
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
|
Phase 1 | |
Not yet recruiting |
NCT02327806 -
The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance
|
N/A | |
Completed |
NCT02639091 -
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06097533 -
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02427490 -
A Problem-Solving Intervention for Family Caregivers in Palliative Oncology
|
N/A | |
Recruiting |
NCT05359848 -
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
|
N/A |